CEA-targeted CAR-T therapy for advanced solid tumors
Part of Cancer, Lungs & breathing, Skin clinical trials.
This trial tests a new CAR-T cell therapy that targets CEA, a protein found on certain cancer cells. It's for people with advanced solid tumors like lung or breast cancer who have not responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have advanced solid tumors such as non-small cell lung cancer or breast cancer.
- Your cancer has gotten worse or you couldn't tolerate at least two prior treatments.
- Your tumor tests positive for CEA, or your blood CEA level is above 10 ng/mL.
- You have at least one measurable tumor or malignant pleural effusion (fluid around the lungs with cancer cells).
- Your overall health is good (ECOG 0-2) and expected survival is at least 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immune cell therapy (CAR-T) designed to attack cancer cells that make a protein called CEA. It may be an option for people with advanced colorectal, esophageal, gastric, or pancreatic cancer who have already tried at least two standard treatments.
This trial tests a new cell therapy called CAR-T that targets cancer cells with a protein called CEA. It is for people with certain advanced cancers that have not responded to standard treatments.
This trial tests a new treatment called CAR-T cells that are designed to find and attack cancer cells carrying a protein called CEA. It is for people with advanced colorectal, esophageal, stomach, or pancreatic cancer who have already tried other treatments.
This trial tests a new type of immune cell therapy (called CAR-T) that targets a protein called CEA on cancer cells. It is for people with advanced colorectal, esophageal, stomach, or pancreatic cancer who have already tried standard treatments without success.
This trial tests a new type of immune therapy called CAR-T cells that are designed to attack lung cancer cells with a specific marker called CEA. It may be an option for people with advanced lung cancer who have already tried other treatments.
This early-stage trial tests a special immune cell treatment (CAR T cells) designed to target and attack lung cancer cells that have a protein called CEA on their surface. It's for people with advanced lung cancer who have already tried at least two standard treatments without success.
Hear when a new NSCLC (Advanced Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.